Skip to main content

Table 1 Demographic and clinical characteristics of patients at baseline (N = 51)

From: Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

Characteristic n (%)
Age, years
 Median 66
 Range 35–74
ECOG performance status
 0 31 (60.8)
 1 10 (19.6)
 2 10 (19.6)
Tumor status
 Stage IV 19 (37.3)
 Recurrence 32 (62.7)
Status of menopause
 Premenopause 8 (15.7)
 Postmenopause 43 (84.3)
Histopathological types  
 Common 49 (96.1)
 Special 2 (3.9)
Hormone receptor status  
 ER-positive 42 (82.4)
 ER-negative 9 (17.6)
 PgR-positive 38 (74.5)
 PgR-negative 13 (25.5)
 Triple-negative (ER, PgR, HER2) 9 (17.6)
Pre- or postoperative treatment
 Anthracycline 16 (31.4)
 Paclitaxel 4 (7.8)
 Docetaxel 12 (23.5)
 Hormone therapy 27 (52.9)
Hormone therapy after recurrence 36 (70.6)
First-line chemotherapy 34 (66.7)
Second-line chemotherapy
 Anthracycline 6 (11.8)
 Oral 5-fluorouracil 11 (21.5)
Number of metastases
 1 7 (13.7)
 2 10 (19.6)
 3 13 (25.5)
 4 5 (9.8)
 5 10 (19.6)
 6–8 6 (11.8)
Dominant site of metastases
 Visceral 42 (82.4)
 Nonvisceral 9 (17.6)
Site of metastasis
 Bone 35 (68.6)
 Liver 32 (62.7)
 Local lymph node 27 (52.9)
 Lung 21 (41.2)
 Local lesion 17 (33.3)
 Distal lymph node 15 (29.4)
 Pleural effusion 10 (19.6)
 Pleura 6 (11.8)
 Brain 2 (3.9)
 Contralateral mamma 2 (3.9)
 Cardiac effusion 1 (2.0)
 Spleen 1 (2.0)
 Pulmonary lymphangitis 1 (2.0)
 Skin 1 (2.0)
 Adrenal 1 (2.0)
  1. ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2